⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Official Title: A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy

Study ID: NCT03769506

Study Description

Brief Summary: A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy

Detailed Description: The study will have an Experimental Arm and a Control Arm. Experimental Arm: Patients may receive repeated ASP-1929 PIT interventions for up to a maximum of 8 cycles within a period of up to 12 months after randomization until the patient has complete remission, progressive disease that is no longer amendable to study treatment, patient experiences intolerable side effects, or patient discontinues study treatment. Repeat ASP-1929 treatment cycles will be administered no less than 4 weeks from the previous ASP-1929 infusion. Control Arm: Patients may be treated with physician's choice standard of care until the patient has progressive disease, patient experiences intolerable side effects, discontinues study treatment, or chooses to withdraw.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

University of South Florida, Tampa, Florida, United States

Grady Health, Atlanta, Georgia, United States

University of Kentucky, Albert B. Chandler Medical Center, Lexington, Kentucky, United States

William Beaumont Hospital, Royal Oak, Michigan, United States

Thomas Jefferson University - Sidney Kimmel Medical College, Philadelphia, Pennsylvania, United States

University of Pennsylvania, Philadelphia, Pennsylvania, United States

Vanderbilt University, Nashville, Tennessee, United States

MD Anderson Cancer Center, Houston, Texas, United States

Kailash Cancer Hospital and Research Center, Vadodara, Gujarat, India

Cancer Institute (W.I.A), Chennai, Tamilnadu, India

Aichi Cancer Center, Nagoya-shi, Aichi, Japan

National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan

Hokkaido University Hospital, Sapporo-shi, Hokkaido, Japan

Okayama University Hospital, Okayama-shi, Okayama, Japan

National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

National Taiwan University Hospital, Zhongzheng, Taipei, Taiwan

China Medical University Hospital, Taichung, , Taiwan

Taichung Veterans General Hospital, Taichung, , Taiwan

Chang Gung Memorial Hospital, Taoyuan, , Taiwan

City Clinical Hospital #4, Dnipro, , Ukraine

Contact Details

Name: Naomi Schechter

Affiliation: Rakuten Medical

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: